Literature DB >> 10573522

Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation.

J M Llovet1, J Fuster, J Bruix.   

Abstract

Liver transplantation is proposed as the best therapy for early hepatocellular carcinoma in cirrhotic patients. However, the confrontation with the results obtained by surgical resection has never been done on an intention-to-treat basis. Between 1989 and 1997, 164 out of 1,265 patients with hepatocellular carcinoma were evaluated for surgery. Seventy-seven (48 men, mean 61 years of age, 74 Child-Pugh class A, size 33 +/- 18 mm) were resected (first line option) and 87 (65 men, mean 55 years of age, 50 Child-Pugh class B/C, size 24 +/- 14 mm) were selected for transplantation. The 1-, 3-, and 5-year "intention-to-treat" survival was 85%, 62%, and 51% for resection and 84%, 69%, and 69% for transplantation (8 drop-outs on waiting list). Bilirubin and clinically relevant portal hypertension were independent survival predictors after resection. Thereby, the 5-year survival of the best candidates (absence of clinically relevant portal hypertension, n = 35) was 74%, whereas it was 25% for the worst candidates (portal hypertension and bilirubin >/=1 mg/dL, n = 27) (P <.00001). The variable "drop-out on waiting list" was the sole survival predictor after transplantation. The 2-year survival rate of patients evaluated for transplantation was 84% in the 1989 to 1995 period (mean waiting time, 62 days; no drop-outs) and 54% during 1996 to 1997 (mean waiting time, 162 days; 8 drop-outs)(P <.003). This outcome was significantly lower than that of the best candidates for resection (P =.002). In conclusion, a proper selection of candidates for resection promotes better results than transplantation, in which the results are significantly hampered by the growing incidence of drop-outs because of the increasing waiting time.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10573522     DOI: 10.1002/hep.510300629

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  376 in total

Review 1.  Treatment strategies for hepatocellular carcinoma in cirrhosis.

Authors:  W Scott Helton; Adrian Di Bisceglie; Ravi Chari; Myron Schwartz; Jordi Bruix
Journal:  J Gastrointest Surg       Date:  2003 Mar-Apr       Impact factor: 3.452

2.  Benefits of laparoscopic liver resection in patients with hepatocellular carcinoma and portal hypertension: a case-matched study.

Authors:  Víctor Molina; Jaime Sampson-Dávila; Joana Ferrer; Constantino Fondevila; Rafael Díaz Del Gobbo; David Calatayud; Jordi Bruix; Juan Carlos García-Valdecasas; Josep Fuster
Journal:  Surg Endosc       Date:  2017-12-07       Impact factor: 4.584

3.  Accelerated carcinogenesis following liver resection in chronically inflamed livers: A window of opportunity for treatment.

Authors:  Amir Sonnenblick; Tamar Zahavi
Journal:  Biomed Rep       Date:  2017-03-30

4.  Resection or transplant-listing for solitary hepatitis C-associated hepatocellular carcinoma: an intention-to-treat analysis.

Authors:  Hiroshi Sogawa; Brian Shrager; Ghalib Jibara; Parissa Tabrizian; Sasan Roayaie; Myron Schwartz
Journal:  HPB (Oxford)       Date:  2012-08-30       Impact factor: 3.647

Review 5.  Hepatocellular carcinoma: is current therapy really altering outcome?

Authors:  P J Johnson
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

Review 6.  Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation.

Authors:  Maurizio Pompili; Giampiero Francica; Francesca Romana Ponziani; Roberto Iezzi; Alfonso Wolfango Avolio
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

Review 7.  Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols.

Authors:  Danijel Galun; Dragan Basaric; Marinko Zuvela; Predrag Bulajic; Aleksandar Bogdanovic; Nemanja Bidzic; Miroslav Milicevic
Journal:  World J Hepatol       Date:  2015-09-18

8.  Simulation modeling of the impact of proposed new simultaneous liver and kidney transplantation policies.

Authors:  Yaojen Chang; Lorenzo Gallon; Kirti Shetty; Yuchia Chang; Colleen Jay; Josh Levitsky; Bing Ho; Talia Baker; Daniela Ladner; John Friedewald; Michael Abecassis; Gordon Hazen; Anton I Skaro
Journal:  Transplantation       Date:  2015-02       Impact factor: 4.939

9.  Comparative effectiveness of liver transplant strategies for end-stage liver disease patients on renal replacement therapy.

Authors:  Yaojen Chang; Lorenzo Gallon; Colleen Jay; Kirti Shetty; Bing Ho; Josh Levitsky; Talia Baker; Daniela Ladner; John Friedewald; Michael Abecassis; Gordon Hazen; Anton I Skaro
Journal:  Liver Transpl       Date:  2014-09       Impact factor: 5.799

10.  Assessment of treatment outcomes based on tumor marker trends in patients with recurrent hepatocellular carcinoma undergoing trans-catheter arterial chemo-embolization.

Authors:  Takuma Arai; Akira Kobayashi; Ayumi Ohya; Masaaki Takahashi; Takahide Yokoyama; Akira Shimizu; Hiroaki Motoyama; Norihiko Furusawa; Tsuyoshi Notake; Noriyuki Kitagawa; Hiroshi Sakai; Hiroshi Imamura; Masumi Kadoya; Shin-Ichi Miyagawa
Journal:  Int J Clin Oncol       Date:  2013-11-12       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.